Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IACH 2021 | State-of-the-art therapies for CLL

Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, comments on the chronic lymphocytic leukemia (CLL) treatment landscape and suggests how these therapies may evolve in the future. Prof. Kater argues that despite significant growth in terms of drugs and treatment combinations for CLL, chemotherapy is still relevant for patients with a mutation in IgVH. In addition, Prof. Kater underlines the necessity of focusing on personalizing these novel therapies for each patient. This interview took place at the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH), which took place virtually in 2021.

Disclosures

Arnon Kater, MD, PhD, has participated in advisory boards and/or received research grants from Abbvie, BMS, Janssen, Roche/Genentech and Astra Zeneca; and has received speakers fees from Abbvie.